CompletedPhase 1NCT06633757

Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

Studying Primary ciliary dyskinesia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
ReCode Therapeutics
Principal Investigator
John Matthews, MBBS, MCRP, PhD
ReCode Therapeutics, Inc.
Intervention
RCT1100(drug)
Enrollment
14 enrolled
Eligibility
18-75 years · All sexes
Timeline
20242025

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06633757 on ClinicalTrials.gov

Other trials for Primary ciliary dyskinesia

Additional recruiting or active studies for the same condition.

See all trials for Primary ciliary dyskinesia

← Back to all trials